Dyne Therapeutics (NASDAQ:DYN) Price Target Cut to $16.00 by Analysts at JPMorgan Chase & Co.

Dyne Therapeutics (NASDAQ:DYN) had its target price cut by JPMorgan Chase & Co. from $17.00 to $16.00 in a report issued on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

Several other equities research analysts have also recently weighed in on DYN. Oppenheimer upgraded Dyne Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $11.00 to $40.00 in a report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Wednesday, October 8th. Stifel Nicolaus raised their price target on shares of Dyne Therapeutics from $36.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Robert W. Baird set a $30.00 price objective on shares of Dyne Therapeutics in a research report on Monday, December 8th. Finally, HC Wainwright increased their target price on shares of Dyne Therapeutics from $46.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.41.

Dyne Therapeutics Trading Down 0.7%

Shares of DYN stock opened at $16.58 on Tuesday. The company has a market capitalization of $2.37 billion, a PE ratio of -4.53 and a beta of 1.32. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $25.00. The business’s fifty day moving average is $19.43 and its 200 day moving average is $15.62. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05. On average, equities research analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently bought and sold shares of the stock. Aberdeen Group plc boosted its position in Dyne Therapeutics by 99.0% during the 4th quarter. Aberdeen Group plc now owns 1,108,145 shares of the company’s stock valued at $21,675,000 after acquiring an additional 551,412 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Dyne Therapeutics by 1,006.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 10,499 shares of the company’s stock valued at $205,000 after purchasing an additional 9,550 shares during the period. Aegis Wealth Management LLC boosted its position in shares of Dyne Therapeutics by 52.1% during the fourth quarter. Aegis Wealth Management LLC now owns 75,908 shares of the company’s stock valued at $1,485,000 after purchasing an additional 26,000 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Dyne Therapeutics during the fourth quarter valued at approximately $5,191,000. Finally, JPMorgan Chase & Co. grew its stake in Dyne Therapeutics by 9.0% in the third quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock worth $42,570,000 after purchasing an additional 278,466 shares during the period. 96.68% of the stock is owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.